Mostrar el registro sencillo del ítem
dc.contributor.author | Carnero Contentti, Edgar | |
dc.contributor.author | López, Pablo Adrián | |
dc.contributor.author | Pappolla, Agustín | |
dc.contributor.author | Alonso, Ricardo | |
dc.contributor.author | Silva, Berenice Anabel | |
dc.contributor.author | Deri, Norma | |
dc.contributor.author | Balbuena Aguirre, María Eugenia | |
dc.contributor.author | Burgos, Marcos | |
dc.contributor.author | Luetic, Geraldine G. | |
dc.contributor.author | Alvez Pinheiro, Amelia | |
dc.contributor.author | Cabrera, Mariela | |
dc.contributor.author | Hryb, Javier Pablo | |
dc.contributor.author | Nofal, Pedro G. | |
dc.contributor.author | Pestchanker, Claudia | |
dc.contributor.author | Vrech, Carlos | |
dc.contributor.author | Tavolini, Darío | |
dc.contributor.author | Marrodán, Mariano | |
dc.contributor.author | Ysrraelit, María Célica | |
dc.contributor.author | Correale, Jorge | |
dc.contributor.author | RelevarEM investigators | |
dc.date.accessioned | 2024-02-20T11:28:21Z | |
dc.date.available | 2024-02-20T11:28:21Z | |
dc.date.issued | 2023-12-30 | |
dc.identifier.citation | Carnero Contentti E, López PA, Pappolla A, Alonso R, Silva B, Deri N, Balbuena ME, Burgos M, Luetic G, Alvez Pinheiro A, Cabrera M, Hryb J, Nofal P, Pestchanker C, Vrech C, Tavolini D, Tkachuk V, Zanga G, Marrodan M, Ysrraelit MC, Correale J, Carrá A, Federico B, Garcea O, Fernandez Liguori N, Patrucco L, Cristiano E, Giunta D, Alonso Serena M, Rojas JI; on behalf RelevarEM. Incidence of SARS-CoV-2 infection in patients with multiple sclerosis who received SARS-CoV-2 vaccines and are under treatment with high-efficacy therapies in Argentina. Neurol Sci. 2024 Feb;45(2):379-389. doi: 10.1007/s10072-023-07282-x. Epub 2023 Dec 30. | es_ES |
dc.identifier.uri | https://doi.org/10.1007/s10072-023-07282-x | |
dc.identifier.uri | https://repositorio.fleni.org.ar/xmlui/handle/123456789/998 | |
dc.description.abstract | We aimed to evaluate the incidence of SARS-CoV-2 breakthrough infection of SARS-CoV-2 vaccines in people with MS (PwMS) on high-efficacy disease-modifying therapies (HET) included in the national MS registry in Argentina (RelevarEM). Methods: Non-interventional, retrospective cohort study that collected information directly from RelevarEM. Adult PwMS who had been treated for at least 6 months with a HET (ocrelizumab, natalizumab, alemtuzumab, cladribine) who had received at least two doses of SARS-CoV-2 vaccines available in Argentina were included. Full course of vaccination was considered after the second dose of the corresponding vaccines. Cumulative incidence of SARS-CoV-2 infection was reported for the whole cohort by Kaplan-Meier survival curves (which is expressed in percentage) as well as incidence density (which is expressed per 10.000 patients/day with 95% CI). Results: Two hundred twenty-eight PwMS were included. Most frequent first and second dose received was AstraZeneca vaccine, followed by Sputnik vaccine. Most frequent HETs used in included patients were cladribine in 79 (34.8%). We found an incidence density of breakthrough COVID-19 infection of 3.5 × 10.000 patients/day (95% CI 2.3-6.7) after vaccination in Argentina. We described the incidence rate after vaccination for every HET used, it being significantly higher for ocrelizumab compared with other HETs (p = 0.005). Only five patients presented a relapse during the follow-up period with no differences regarding the pre-vaccination period. Conclusions: We found an incidence density of breakthrough COVID-19 infection of 3.5 × 10.000 patients/day (95% CI 2.3-6.7) after vaccination in Argentina. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Springer-Verlag Italia | es_ES |
dc.subject | Esclerosis Múltiple | es_ES |
dc.subject | Multiple Sclerosis | es_ES |
dc.subject | Argentina | es_ES |
dc.title | Incidence of SARS-CoV-2 infection in patients with multiple sclerosis who received SARS-CoV-2 vaccines and are under treatment with high-efficacy therapies in Argentina | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.description.fil | Fil: Marrodán, Mariano. Fleni. Departamento de Neurología. Servicio de Neuroinmunología y Enfermedades Desmielinizantes; Argentina. | |
dc.description.fil | Fil: Ysrraelit, María Célica. Fleni. Departamento de Neurología. Servicio de Neuroinmunología y Enfermedades Desmielinizantes; Argentina. | |
dc.description.fil | Fil: Correale, Jorge. Fleni. Departamento de Neurología. Servicio de Neuroinmunología y Enfermedades Desmielinizantes; Argentina. | |
dc.relation.ispartofNUMBER | 2 | |
dc.relation.ispartofPAGINATION | 379-389. | |
dc.relation.ispartofTITLE | Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology | |
dc.relation.ispartofISSN | 1590-3478 | |
dc.type.snrd | info:ar-repo/semantics/artículo | es_ES |